Hungarian Immunology

[Features of serum carnitine ester profile in systemic sclerosis]

TALIÁN Csaba Gábor, KISS György Csaba, MELEGH Béla, CZIRJÁK László

MARCH 20, 2009

Hungarian Immunology - 2009;8(01)

[AIMS - Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, fibrosis, inflammatory changes, and late stage atrophy with obliterative vasculopathy. Clinically it has two distinct subtypes, limited (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc). Carnitine is an essential metabolite with ester forming capability. We investigated the possible relationship between carnitine metabolism and systemic sclerosis, stratified by disease subgroups. PATIENTS AND METHODS - We performed comparative measurements of carnitine profile in 107 systemic sclerosis patients (78 lcSSc and 29 dcSSc) and 47 healthy controls using triple quadrupol ESI mass spectrometry. RESULTS - C2-, C3-, C8-, C10:1- and C10-carnitine ester levels were moderately decreased in the serum of the patients, while C5- and C6-carnitine ester concentrations increased in both types of the disease compared with controls; as a summary, these changes altogether led to reduced total carnitine ester concentrations. Free carnitine level remained unaffected. CONCLUSIONS - These results show that both types of SSc have a moderate influence on shortand medium chain carnitine ester metabolism, but likely do not affect the quantity of the free carnitine reserves.]

COMMENTS

0 comments

Further articles in this publication

Hungarian Immunology

[Diagnosis and treatment of the Raynaud-syndrome]

CSIKI Zoltán

Hungarian Immunology

[FORTHCOMING CONFERENCES]

Hungarian Immunology

[PAPER REVIEW]

VÁNCSA Andrea

Hungarian Immunology

[Károly Rauss, the immunologist]

RALOVICH Béla

Hungarian Immunology

[DROP2 - Interdisciplinary forum among rheumatologists, gastroenterologists, hematologists and oncologists Scientific program]

All articles in the issue

Related contents

Lege Artis Medicinae

[PATHOLOGICAL FEATURES OF SYSTEMIC SCLEROSIS]

VARJÚ Cecília, KUMÁNOVICS Gábor, CZIRJÁK László

[Systemic sclerosis is characterized by fibrosis and subsequent atrophy of the skin and several internal organs as well as by generalized obliterative vasculopathy. The ethiology of systemic sclerosis is not quite clear yet, but the role of certain environmental factors, genetic properties and microchimaerism has been proven. Vasculopathy is a key feature that includes both functional changes (Raynaud's phenomenon) and morphological alterations (lesion of the endothel). The triggering event is the activation of endothelial cells. This is followed by an autoimmune inflammatory process causing vascular lesion, which will eventually lead to progressive pathologic fibrosis with increased deposition of collagen and intercellular matrix proteins. Normal tissues of vital internal organs will gradually loose structure, become atrophic and irreversibly damaged. In the treatment of systemic sclerosis the most significant achievements of the past decade have been made in the therapy and prevention of scleroderma renal crisis, pulmonary arterial hypertension and other vascular complications, resulting in higher survival rates and better quality of life. In pulmonary fibrosis the beneficial effect of cyclophosphamide therapy has been proven. Today, research focuses on new therapeutic approaches based on the recently clarified molecular pathological processes, as well as on laboratory and clinical markers that predict the activity of the disease or the efficiency of therapy. The aim of the present paper is to review current knowledge on the pathology of systemic sclerosis and provide help in the diagnosis, therapy and follow-up of the disease.]

Lege Artis Medicinae

[Up-to-date management of systemic sclerosis]

SZŰCS Gabriella

[Systemic sclerosis is a chronic autoimmune disease characterized by three major features: widespread fibrosis in the skin and internal organs, a non-inflammatory small vessel obliterative vasculopathy and immunological activation with disease-specific autoantibodies. It is necessary to take a systematic approach to the diagnosis and evaluation of each case in order to provide appropriate treatment. Disease-modifying approaches can be classified according to the underlying pathogenic process. Thus vascular therapies include agents used for Raynaud’s phenomenon, critical digital ischaemia and organ-based vascular complications such as scleroderma renal crisis and pulmonary hypertension. Immunosuppressive drugs are used in lung involvement or rapid skin progression. The results of different anti-fibrotic therapies are controversial. Finally in managing organ-based manifestations and complications a multidisciplinary approach to the therapy is useful with patient education as an integral component of successful management.]

Clinical Neuroscience

A rare entity of acquired idiopathic generalised anhidrosis which has been successfully treated with pulse steroid therapy: Does the histopathology predict the treatment response?

ÖKTEM Özdemir Ece, ÇANKAYA Şeyda, UYKUR Burak Abdullah, ERDEN Simsek Nazan, YULUG Burak

Acquired idiopathic generalised anhidrosis is an uncommon sweating disorder characterized by loss of sweating in the absence of any neurologic, metabolic or sweat gland abnormalities. Although some possible immunological and structural mechanisms have been proposed for this rare entity, the definitive pathophysiology is still un­clear. Despite some successfully treated cases with systemic corticosteroid application, the dose and route of steroid application are controversial. Here, we present a 41-year-old man with lack of genera­lised sweating who has been successfully treated with high dose pulse intravenous prednisolone. We have discussed his clinical and histopathological findings as well as the treatment options in view of the current literature.